**DOCKET NO.: ADOL-0497** 

**PATENT** 

JAN 2 3 2003 2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kruse, et al.

Serial No.: 09/769,450

Filing Date: January 26, 2001

ming Date. Samuary 20, 2001

Kappa Agonist Compounds, Pharmaceutical Formulations And Method Of

Confirmation No.: 4357

**Group Art Unit: 1617** 

Examiner: Wang, Shengjun

**Prevention And Treatment Of Pruritus Therewith** 

Of to ale

# TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, **Adolor Corporation**, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. **5,981,513**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that

it and the prior patent are commonly owned. This agreement runs with any patent granted on

the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated

01/27/2003 AWONDAF1 00000065 233050 0976945

03 FC:2814

55.00 CH

## 15

**PATENT** 

prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

(Check either box 1 or 2 below, if appropriate)

- 1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
  - The required statement under 37 CFR § 3.73(b) is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.

## **FEE STATUS**

- 3. Applicant(s) has previously claimed small entity status under 37 CFR §

  1.27.
- 4. Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:

an Independent In	ventor
-------------------	--------

DOC	KET NO	O.: AD	OL-04	97 - 3 -	PATENT
				a Nonprofit Organization	
				Small Entity - <u>\$55.00</u>	
		5.	Other	than a Small Entity - <u>\$110.00</u>	
Date:				Bruce A. Peacock Name (Please type or print)	
				President and Chief Executi Title	ve Officer
				Signature	

**DOCKET NO.: ADOL-0497** 

2 3 2003

# IN THE UNITED STATES PATENT AND TRADEMARK OFF

In Re Application of:

Kruse, et al.

Serial No.: 09/769,450

Filing Date: January 26, 2001

Confirmation No.: 4357 **Group Art Unit: 1617** 

Examiner: Wang, Shengjun

Kappa Agonist Compounds, Pharmaceutical Formulations And Method Of

**Prevention And Treatment Of Pruritus Therewith** 

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, Adolor Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,763,445. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated

01/27/2003 AWONDAF1 00000065 233050

02 FC:2814

55.00 CH

**PATENT** 

DOCKET NO.: ADOL-0497 -2- PATENT

prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

(Check either box 1 or 2 below, if appropriate)

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

The required statement under 37 CFR § 3.73(b) is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.

#### FEE STATUS

3. Applicant(s) has previously claimed small entity status under 37 CFR §1.27.

4. Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:

a	n Independent	Inventor
---	---------------	----------

DOCI	KETN	O.: AD	OL-04	97 - 3 -	PATENT
				a Nonprofit Organization	
				Small Entity - <b>\$55.00</b>	
		5.	Other	than a Small Entity - \$110.00	
Date:					A. Peacock (Please type or print)
				Preside Title	ent and Chief Executive Officer
				Signati	ire

OCKET NO.: ADOL-0497

**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kruse, et al.

Serial No.: 09/769,450

Filing Date: January 26, 2001

Kappa Agonist Compounds, Pharmaceutical Formulations And Method Of

Confirmation No.: 4357

Examiner: Wang, Shengjun

Group Art Unit: 1617

**Prevention And Treatment Of Pruritus Therewith** 

# TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, Adolor Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,028,063. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated DOCKET NO.: ADOL-0497 - 2 - PATENT

prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

(Check either box 1 or 2 below, if appropriate)

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

The required statement under 37 CFR § 3.73(b) is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.

## **FEE STATUS**

3. Applicant(s) has previously claimed small entity status under 37 CFR §1.27.

4. Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:

an Independent Inventor

DOCI	SEI N	<b>U.</b> : .	ADOL-04	91 - 3 -	PATENT
				a Nonprofit Organization	
				Small Entity - <u>\$55.00</u>	
		5.	Other	than a Small Entity - \$110.00	
Date:				Bruce A. Peacock Name (Please type or print)	
				President and Chief Executive Title	re Officer
				Signature	<u> </u>

FBOCKET NO.: ADOL-0497

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No.: 4357

**Group Art Unit: 1617** 

PATENT

In Re Application of:

Kruse, et al.

Serial No.: 09/769,450

Filing Date: January 26, 2001

Examiner: Wang, Shengjun

Kappa Agonist Compounds, Pharmaceutical Formulations And Method Of **Prevention And Treatment Of Pruritus Therewith** 

> TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, Adolor Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,180,623. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated DOCKET NO.: ADOL-0497 - 2 - PATENT

prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

(Check either box 1 or 2 below, if appropriate)

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

The required statement under 37 CFR § 3.73(b) is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.

## **FEE STATUS**

3. Applicant(s) has previously claimed small entity status under 37 CFR §
 1.27.
 4. Applicant(s) by its/their undersigned attorney, claims small entity

status under 37 CFR § 1.27 as:

an Independent Inventor

DOCI	KEIN	U.: A	DOL-04	97 - 3 -	PATENT
				a Nonprofit Organization	
				Small Entity - <b>\$55.00</b>	
		5.	Other	than a Small Entity - <u>\$110.00</u>	
Date:				Bruce A. Peacock Name (Please type or print)	
				President and Chief Executive Title	ve Officer
				Signature	